Granulocyte Colony-Stimulating Factor Improves the Antileukemic Efficacy of the Sequential High-Dose Cytosine Arabinoside and Mitoxantrone Regimen (S-HAM) in Patients Younger than 60 Years with High-Risk Acute Myeloid Leukemia

[1]  A. Ganser,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[2]  B. Löwenberg,et al.  Application of myeloid growth factors in the treatment of acute myeloid leukemia , 1997, Leukemia.

[3]  J. Rowe,et al.  Hematopoietic growth factors in acute leukemia , 1997, Leukemia.

[4]  Edward J. Lee,et al.  Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. , 1997, Blood.

[5]  C. Schiffer.  Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. , 1996, Blood.

[6]  M. Grever,et al.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.

[7]  M. Sanz,et al.  Filgrastim for the treatment of leukemia relapse after bone marrow transplantation. , 1996, Bone marrow transplantation.

[8]  R. Geller,et al.  Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[10]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[11]  J. Armitage,et al.  Clinical applications of hematopoietic growth factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Jinnai,et al.  Suppression of the development of murine myeloid leukemia with granulocyte colony-stimulating factor by inducing apoptosis of leukemic cells. , 1994, Leukemia.

[13]  Masahiro Yoshida,et al.  A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments] , 1994 .

[14]  P. Thall,et al.  Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Andreeff,et al.  Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. , 1993, The New England journal of medicine.

[16]  M. Tanimoto,et al.  No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Japan Adult Leukemia Study Group. , 1993, Blood.

[17]  J. Lotem,et al.  Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. , 1992, Blood.

[18]  Y. Yamasaki,et al.  PROBABLE IN VIVO INDUCTION OF DIFFERENTIATION BY RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (rhG‐CSF) IN ACUTE PROMYELOCYTIC LEUKAEMIA (APL) , 1991, British journal of haematology.

[19]  K. Meguro,et al.  COMPLETE REMISSION IN ACUTE MYELOID LEUKAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR AND HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE , 1991, British journal of haematology.

[20]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[21]  W. Hiddemann,et al.  Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. , 1990, Leukemia.

[22]  S. Asano,et al.  Effects of recombinant human granulocyte colony stimulating factor (rG-CSF) on murine myeloid leukemia: stimulation of proliferation of leukemic cells in vitro and inhibition of development of leukemia in vivo. , 1989, Leukemia.

[23]  H. Toki,et al.  REMISSION IN HYPOPLASTIC ACUTE MYELOID LEUKAEMIA INDUCED BY GRANULOCYTE COLONY-STIMULATING FACTOR , 1989, The Lancet.

[24]  M. Minden,et al.  The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. , 1987, Blood.

[25]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[27]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[28]  T. Mcelwain,et al.  ORAL NON-ABSORBED ANTIBIOTICS PREVENT INFECTION IN ACUTE NON-LYMPHOBLASTIC LEUKÆMIA , 1977, The Lancet.

[29]  W. Hiddemann,et al.  Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study , 1998 .

[30]  W. Hiddemann,et al.  Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. , 1997, Seminars in oncology.

[31]  Wolfgang Kern,et al.  High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias , 1997, Cancer.

[32]  D. Scheinberg,et al.  Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. , 1996, Leukemia.

[33]  J. Klein,et al.  Chemotherapy versus transplants for acute myelogenous leukemia in second remission. , 1996, Leukemia.

[34]  W. Hiddemann,et al.  Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. , 1992, Leukemia.

[35]  M. Ono,et al.  Prolonged survival of mice with myeloid leukemia by subcutaneous injection of recombinant human G-CSF. , 1989, Leukemia research.